Study Shows Clearing Amyloid-Beta Plaques in Alzheimer’s Brains May Not Restore Brain Functions
For decades, scientists have focused on targeting the sticky protein clumps that accumulate in the brains of individuals with Alzheimer’s disease as a potential treatment approach. However, a recent study suggests that clearing away amyloid-beta plaques may not necessarily lead to the restoration of key brain functions.
Researchers at the Osaka Metropolitan University in Japan conducted a study involving 13 individuals with Alzheimer’s disease who were treated with the new drug lecanemab. Magnetic resonance imaging (MRI) scans were used to assess the effects of the drug on the brain.
The findings revealed that even though lecanemab reduced amyloid-beta levels in the brain, it did not improve the function of the glymphatic system – the brain’s waste clearance mechanism that is impaired in individuals with Alzheimer’s. The glymphatic system is responsible for removing excess amyloid-beta plaques through waves of cerebrospinal fluid.
Medical researcher Tatsushi Oura from Osaka Metropolitan University stated, “Even when amyloid-beta is reduced by lecanemab, impairment of the glymphatic system may not recover within the short-term.”
The study highlights the complex nature of Alzheimer’s disease, which involves various potential causes, risk factors, and symptoms. While amyloid-beta and tau protein buildup are hallmark signs of the disease, researchers are still investigating whether they are the cause of Alzheimer’s, a result of the disease, or both.
Although lecanemab showed efficacy in reducing amyloid-beta levels, it did not lead to improvements in glymphatic system function after three months of treatment. The drug appears to slow down the progression of Alzheimer’s but may not reverse the damage already done to the brain’s waste recycling mechanism.
The researchers emphasized that disease-modifying therapies can help reduce plaque burden and slow cognitive decline but may not restore lost brain function. Neuronal damage and deficits in the clearance system are often well-established in individuals with Alzheimer’s.
Past trials have demonstrated that lecanemab is most effective when administered early in the disease process, highlighting the importance of early detection of dementia symptoms. Future research will focus on expanding the study parameters to examine the drug’s effects on Alzheimer’s at different stages and durations of treatment.
Overall, the study sheds light on the intricate nature of Alzheimer’s disease and the need for further research to better understand how to effectively treat and manage the condition.
The research findings have been published in the Journal of Magnetic Resonance Imaging.
